MeSH D015535 - psoriatic arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Abbott Biotherapeutics | Adalimumab | Trudexa |  | 2003-09-01 |  |  |
| AbbVie | Adalimumab | Humira |  | 2002-12-31 | $8,993 M | Y2024 |
| Risankizumab | Skyrizi |  | 2019-04-26 | $11,718 M | Y2024 | |
| Alkem Laboratories | Apremilast | Apremilast |  | 2021-09-21 |  |  |
| Amgen | Adalimumab | Amgevita |  | 2017-03-21 |  |  |
| Adalimumab | Amjevita |  | 2016-09-23 |  |  | |
| Infliximab | Avsola |  | 2019-12-06 |  |  | |
| Apremilast | Otezla | 2023-03-19 | 2014-03-21 | $2,126 M | Y2024 | |
| Adalimumab | Solymbic |  | 2017-03-22 |  |  | |
| Ustekinumab | Wezlana |  | 2023-10-31 |  |  | |
| Amneal Pharmaceuticals | Apremilast | Apremilast |  | 2021-06-30 |  |  |
| Annora Pharma | Apremilast | Apremilast |  | 2023-07-26 |  |  |
1
2
3
4
5
6
...
8
>
Clinical Trials
Historical Success Rate
Phase 1
62%13/21
Phase 2
63%17/27
Phase 3
90%44/49
Approved: 20Overall Success rate: 35%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use